Skip to main content
. 2022 Oct 31;12(2):156–170. doi: 10.1159/000527759

Fig. 3.

Fig. 3

Comparison of treatment responses and PFS between unresectable HCC patients with or without low baseline MIG (CXCL9) treated with lenvatinib. a Comparison of baseline serum CXCL9 levels between patients with or without PD or objective responses to lenvatinib. b Comparison of rate of PD and objective response (OR) to lenvatinib between patients with ≥333 pg/mL and <333 pg/mL at baseline CXCL9. c PFS and overall survival (OS) stratified by <308 pg/mL the baseline MIG. Median PFS in patients with ≥308 pg/mL and <308 pg/mL baseline MIG was 168 and 219 days, respectively (HR: 1.30, 95% CI: 0.82–2.06, p = 0.14). Median OS in patients with ≥308 pg/mL and <308 pg/mL baseline MIG was 477 and 740 days, respectively (HR: 1.55, 95% CI: 0.89–2.71, p = 0.096).